A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010

Trial Profile

A Randomized, Double-blind, Placebo-controlled, 2-way Crossover Study in Subjects With Parkinson's Disease With Moderate to Severe Levodopa-induced Dyskinesia, to Assess the Efficacy, Safety/Tolerability and Pharmacokinetics of JM-010

Completed
Phase of Trial: Phase II

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs JM 010 (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Bukwang Pharmaceutical
  • Most Recent Events

    • 12 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 15 Jun 2015 According to a Bukwang Pharma and Contera Pharma media release, the first patient was dosed for this study in June 2015 and the company has planned to complete the dosing of at least 25 patients by first quarter 2016 followed by reporting later in H1 2016.
    • 27 May 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top